-
Mashup Score: 0Mantle Cell Lymphoma: Insights and Challenges Slides 2023 - 5 month(s) ago
By: Allen Wilbanks Date: October 03, 2023 Julie Vose, MD, a respected expert in the field of lymphoma, began her presentation by acknowledging the challenging nature of mantle cell lymphoma and introduced herself with the following quote: Thank you very much. So it’s my pleasure to talk about mantle cell lymphoma, a…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Prognostic Value of CAR-HEMATOTOX Score for Treatment Outcomes of Patients With R/R MCL Undergoing CAR T-Cell Therapy - 6 month(s) ago
CAR-HEMATOTOX scores predicted treatment outcomes and toxicity risks among patients with R/R MCL treated with CAR T-cell therapy, according to a multicenter observational study.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0article - 6 month(s) ago
INTRODUCTIONNon-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of lymphoid malignancies that originate from B cells, T cells, or natural killer cells. There are 70 different types of NHL as per the 2016 WHO Classification.[1] Among them, Mantle cell lymphoma (MCL) is one of the rarest varieties, comprising only 6% of NHL.[2] It is more common in males than females (M: F is 4:1 as in 2015)….
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#MantleCellLymphoma (MCL) accounts for less than 1% of head and neck malignancies. Due to its short clinical course, there are limited data on standard treatment protocols. Even with the present treatments, only 30% of patients achieve complete response. https://t.co/f3elQocnEu https://t.co/WTxfwtsYJE
-
-
Mashup Score: 1Pharmacy Forum: Pirtobrutinib (Jaypirca™) - 6 month(s) ago
By Mikaela McCabe, PharmDWhat is pirtobrutinib?Pirtobrutinib is a reversible Bruton tyrosine kinase (BTK) inhibitor that blocks signaling of B-cell antigen receptor and cytokine pathway signaling protein, which are essential for B-cell proliferation and functionality. Pirtobrutinib binds to both wild-type BTK and BTK with C481 mutations. What is pirtobrutinib approved for?Pirtobrutinib is…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0article - 6 month(s) ago
INTRODUCTIONMantle cell lymphoma (MCL) is a B-cell malignancy mainly diagnosed in the elderly population, and more commonly among males. It is among the more recently defined forms of B-cell lymphomas, when the association between centrocytic morphology and the presence of a translocation t(11;14) was made in the 1990s,1 defining what is now classified as MCL.Since then, the lymphoma community…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0article - 6 month(s) ago
1. IntroductionBullous pemphigoid is an autoimmune subepidermal blistering disorder. Mantle cell lymphoma is a B-cell malignancy of a rare type of non-Hodgkin lymphoma. Bullous pemphigoid associated with mantle cell lymphoma is even rarer which may suggest a paraneoplastic phenomenon.[1]2. Case reportA 29-year-old Malay man, a federal plantation supervisor, was admitted with 5 months’ history of…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0article - 6 month(s) ago
INTRODUCTIONNon-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of lymphoid malignancies that originate from B cells, T cells, or natural killer cells. There are 70 different types of NHL as per the 2016 WHO Classification.[1] Among them, Mantle cell lymphoma (MCL) is one of the rarest varieties, comprising only 6% of NHL.[2] It is more common in males than females (M: F is 4:1 as in 2015)….
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#MantleCellLymphoma (MCL) accounts for less than 1% of head and neck malignancies. Due to its short clinical course, there are limited data on standard treatment protocols. Even with the present treatments, only 30% of patients achieve complete response. https://t.co/f3elQocnEu https://t.co/UTfqSP6gyS
-
-
Mashup Score: 0Pharmacy Forum: Pirtobrutinib (Jaypirca™) - 7 month(s) ago
By Mikaela McCabe, PharmDWhat is pirtobrutinib?Pirtobrutinib is a reversible Bruton tyrosine kinase (BTK) inhibitor that blocks signaling of B-cell antigen receptor and cytokine pathway signaling protein, which are essential for B-cell proliferation and functionality. Pirtobrutinib binds to both wild-type BTK and BTK with C481 mutations. What is pirtobrutinib approved for?Pirtobrutinib is…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pirtobrutinib is a reversible BTK inhibitor that blocks B-cell antigen receptor signaling and cytokine pathway signaling protein. It is approved for adults with relapsed or refractory #MantleCellLymphoma after at least two lines of prior systemic therapy. https://t.co/hFisZm9n8n https://t.co/qVmn33gPvz
-
-
Mashup Score: 0Prognostic Significance of Time to POD, Ki67, and MIPI for Patients With R/R Mantle Cell Lymphoma Initiating Second-Line BTK Inhibitor Therapy - 8 month(s) ago
Time to progression of disease, Ki67, and MIPI were strongly associated with survival outcomes among patients with R/R MCL undergoing treatment with second-line BTK inhibitors after rituximab-based chemotherapy.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In the standard-of-care setting, the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.
Source: PubMedCategories: Latest Headlines, Oncologists1Tweet
Dive into the latest insights on Mantle Cell Lymphoma with Julie Vose, MD @NebraskaDoctors. Discover key aspects of diagnosis, treatment, and the evolving landscape of this condition. [slides][video]https://t.co/p1hvcKH7lD #MantleCellLymphoma @MDEducation @Ryan_Fitzpatric https://t.co/iTPgzpqEL0